Company Overview and News

 
Gascoyne’s Dalgaranga project aiming for first gold six weeks ahead of schedule

2018-05-08 australianmining.com.au
Gascoyne Resources is only 10 days from first gold production at the Dalgaranga project in Western Australia, under budget and six weeks ahead of schedule.

 
Gascoyne a month from first gold

2018-04-18 australianmining.com.au
Gascoyne Resources is preparing to deliver first gold at the Dalgaranga project in Western Australia next month.

 
Dalgaranga two months from gold production

2018-03-18 australianmining.com.au
Gascoyne Resources is two months away from producing first gold at the Dalgaranga gold project in Western Australia.

 
Gascoyne’s Dalgaranga gold project ahead of schedule, three months to first gold

2018-02-15 australianmining.com.au
Gold developer Gascoyne Resources has released an update on its Dalgaranga gold project in the Murchison region of Western Australia, saying it is ahead of schedule by a month.

 
Demand for mining services ramps up (Part 2)

2018-01-31 australianmining.com.au
Improved commodity prices led to an increase in mining activity, meaning the expertise of the country’s mining services contractors was in growing demand.

 
Gascoyne signs up EVOL

2018-01-31 businessnews.com.au
Wesfarmers subsidiary EVOL has won a long term contract to supply LNG to the power station and the process plant at Gascoyne Resources’ Dalgaranga gold project in the Murchison region.

 
EVOL secures LNG contract

2018-01-31 businessnews.com.au
Wesfarmers subsidiary EVOL has won a long term contract to supply LNG to the power station and the process plant at Gascoyne Resources’ Dalgaranga gold project in the Murchison region.

 
Demand for mining services ramps up (Part 1)

2018-01-30 australianmining.com.au
Improved commodity prices led to an increase in mining activity, meaning the expertise of the country’s mining services contractors was in growing demand.

 
Where are Australia’s major mining projects?

2018-01-09 australianmining.com.au
The number of committed mining and energy projects in Australia has increased by 21 per cent over the past year.

 
Gascoyne executes Dalgaranga mining contract with NRW

2017-12-12 australianmining.com.au
Gold developer Gascoyne Resources has confirmed that NRW Holdings will be its mining contractor at the Dalgaranga operation in the Murchison region of Western Australia.

 
Zenith to build 15MW power station

2017-12-08 businessnews.com.au
Belmont-based Zenith Energy has signed a power purchase agreement to build a 15-megawatt power station at Gascoyne Resources’ Dalgaranga gold project.

 
Genesis Minerals commences drilling at Barimaia gold project in WA

2017-12-07 australianmining.com.au
A 2500-metre reverse circulation drilling program has been launched by Genesis Minerals at the Barimaia gold project in Western Australia.

 
Gascoyne Resources gain funding for Dalgaranga gold project with $60 million bank loan

2017-12-06 australianmining.com.au
Gascoyne Resources has secured an agreement with Commonwealth Bank of Australia (CBA) and National Australia Bank (NAB) for $60 million in funding for its Dalgaranga gold project in Western Australia.

 
$21m share placement for Gascoyne

2017-11-22 businessnews.com.au
Gascoyne Resources has raised $21 million through a heavily oversubscribed share placement to fund further exploration and development at two of its Western Australian gold projects.

 
$21m share placement for Gascoyne gold projects

2017-11-22 businessnews.com.au
Local explorer Gascoyne Resources has raised $21 million through a heavily oversubscribed share placement to fund further exploration and development at two of its Western Australian gold projects.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

16h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

17h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...